
|Videos|December 15, 2022
Third-Line Treatment Options for HER2+ mBC after Progression on Trastuzumab Deruxtecan
Heather McArthur, MD, describes what treatment options she would consider in the third-line setting for HER2+ mBC.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Olomorasib Earns FDA Breakthrough Therapy in KRAS G12C+ Pancreatic Cancer
2
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
3
Epcoritamab Combo Shows Sustained Remissions in Follicular Lymphoma
4
Why CAR T-Cell Therapy Should Precede Bispecifics in Multiple Myeloma
5























































